1 Nutritional deficiency recapitulates intestinal injury associated with

2 environmental enteric dysfunction in patient-derived Organ Chips

- 3
- 4 Amir Bein^{1,13}, Cicely W. Fadel^{1,2,13}, Ben Swenor¹, Wuji Cao¹, Rani K. Powers¹, Diogo M.
- 5 Camacho^{1,3}, Arash Naziripour¹, Andrew Parsons¹, Nina LoGrande¹, Sanjay Sharma¹, Seongmin
- 6 Kim¹, Sasan Jalili-Firoozinezhad^{1,4}, Jennifer Grant¹, David T. Breault^{2,5,6}, Junaid Iqbal⁷, Asad Ali⁷,
- 7 Lee A Denson^{8,9}, Sean R. Moore¹⁰, Rachelle Prantil-Baun¹, Girija Goyal¹, and Donald E.
- 8 Ingber^{1,11,12*}
- 9
- ¹Wyss Institute for Biologically Inspired Engineering, Harvard University, Boston, MA 02115, USA
- 11 ²Department of Pediatrics, Harvard Medical School, Boston, MA, 02115, USA
- 12 ³Current address: Rheos Medicines, Cambridge, MA, USA
- 13 ⁴Department of Bioengineering and iBB Institute for Bioengineering and Biosciences, Instituto Superior
- 14 Técnico, Universidade de Lisboa, Lisboa, Portugal
- 15 ⁵Division of Endocrinology, Boston Children's Hospital, Boston, MA 02115, USA
- 16 ⁶Harvard Stem Cell Institute, Harvard University, Boston, MA 02139, USA
- ¹⁷ ⁷Department of Paediatrics and Child Health, The Aga Khan University, Karachi 74800, Pakistan
- 18 ⁸Division of Gastroenterology, Hepatology, and Nutrition, Cincinnati Children's Hospital Medical Center,
- 19 Cincinnati, OH, USA.
- ⁹Department of Pediatrics, University of Cincinnati College of Medicine, Cincinnati, OH, USA.
- 21 ¹⁰Division of Pediatric Gastroenterology, Hepatology, and Nutrition, Department of Pediatrics, University
- 22 of Virginia, Charlottesville, USA.
- ²³ ¹¹Harvard John A. Paulson School of Engineering and Applied Sciences, Harvard University, Cambridge,
- 24 MA 02138, USA.
- 25 ¹²Vascular Biology Program and Department of Surgery, Harvard Medical School and Boston Children's
- 26 Hospital, Boston, MA 02115, USA.
- 27 ¹³ These authors contributed equally: Amir Bein, Cicely W. Fadel
- 28 *Address correspondence to: don.ingber@wyss.harvard.edu

29 ABSTRACT

30 Environmental Enteric Dysfunction (EED) is a chronic inflammatory condition of the 31 intestine characterized by villus blunting, compromised intestinal barrier function, and reduced 32 nutrient absorption. Here, we show that key genotypic and phenotypic features of EED-33 associated intestinal injury can be reconstituted in a human intestine-on-a-chip (Intestine Chip) 34 microfluidic culture device lined by organoid-derived intestinal epithelial cells from EED patients 35 and cultured in niacinamide- and tryptophan-deficient (-N/-T) medium. Exposure of EED 36 Intestine Chips to -N/-T deficiencies resulted in transcriptional changes similar to those seen in 37 clinical EED patient samples including congruent changes in six of the top ten upregulated 38 genes. Exposure of EED Intestine Chips or chips lined by healthy intestinal epithelium (healthy 39 Intestine Chips) to -N/-T medium resulted in severe villus blunting and barrier dysfunction, as 40 well as impairment of fatty acid uptake and amino acid transport. EED Intestine Chips exhibited 41 reduced secretion of cytokines at baseline, but their production was significantly upregulated compared to healthy Intestine Chips when exposed to -N/-T deficiencies. The human Intestine 42 43 Chip model of EED-associated intestinal injury may be useful for analyzing the molecular, 44 genetic, and nutritional basis of this disease and can serve as a preclinical model for testing 45 potential EED therapeutics.

46

INTRODUCTION 47

48

49 Environmental Enteric Dysfunction (EED) is a pediatric disorder characterized by chronic 50 intestinal inflammation that is associated with malnutrition, stunted growth, cognitive 51 impairment, and attenuated response to oral vaccines ¹⁻⁵. Previously described as "tropical 52 enteropathy" or "environmental enteropathy", EED has gained renewed interest in recent years

53	due to its devastating effect on millions of children in low-and middle-income countries. The
54	intestine of EED patients commonly exhibits villous atrophy, nutrient malabsorption, barrier
55	dysfunction, and inflammation ^{6,7} . Currently, there is limited mechanistic understanding of the
56	disease, which has hampered efforts to define biomarkers for diagnosis and therapeutics for
57	effective prevention or treatment 8 . For example, deficiencies of micronutrients, such as zinc 9
58	and vitamin A ¹⁰ , may contribute to EED pathophysiology as they are associated with abnormal
59	lactulose-mannitol (L:M) ratios, a measure of intestinal permeability. However, attempts at
60	therapeutic intervention with nutritional replenishment have been disappointing likely due to
61	ongoing intestinal dysfunction ⁸ . Similarly, other dietary interventions, such as administering
62	omega-3 long-chain polyunsaturated fatty acids 11 , optimizing amino acid profiles 12 ,
63	supplementing with multiple micronutrients ¹³ or improving food digestibility through
64	fermentation, hydrolysis, or enzyme supplementation ¹² , also have been tested with limited
65	success.
65 66	success. Beyond its role as a major manifestation of EED, malnutrition is also likely to actively
66	Beyond its role as a major manifestation of EED, malnutrition is also likely to actively
66 67	Beyond its role as a major manifestation of EED, malnutrition is also likely to actively contribute to disease pathophysiology. Murine diets low in the essential amino acid tryptophan
66 67 68	Beyond its role as a major manifestation of EED, malnutrition is also likely to actively contribute to disease pathophysiology. Murine diets low in the essential amino acid tryptophan lead to decreased antimicrobial peptide secretion and increased susceptibility to chemical-
66 67 68 69	Beyond its role as a major manifestation of EED, malnutrition is also likely to actively contribute to disease pathophysiology. Murine diets low in the essential amino acid tryptophan lead to decreased antimicrobial peptide secretion and increased susceptibility to chemical-induced intestinal inflammation ¹⁴ . Low serum tryptophan levels are also linked to stunting in
66 67 68 69 70	Beyond its role as a major manifestation of EED, malnutrition is also likely to actively contribute to disease pathophysiology. Murine diets low in the essential amino acid tryptophan lead to decreased antimicrobial peptide secretion and increased susceptibility to chemical- induced intestinal inflammation ¹⁴ . Low serum tryptophan levels are also linked to stunting in children suffering from EED ^{15,16} . Tryptophan is both a building block for proteins and a
 66 67 68 69 70 71 	Beyond its role as a major manifestation of EED, malnutrition is also likely to actively contribute to disease pathophysiology. Murine diets low in the essential amino acid tryptophan lead to decreased antimicrobial peptide secretion and increased susceptibility to chemical- induced intestinal inflammation ¹⁴ . Low serum tryptophan levels are also linked to stunting in children suffering from EED ^{15,16} . Tryptophan is both a building block for proteins and a precursor for niacin, melatonin, and neurotransmitters, including serotonin and tryptamine ¹⁷ .

75 acid) deficiency also has been implicated as a contributor to EED and other inflammatory 76 intestinal conditions as administration of niacin was shown to ameliorate dextran sodium 77 sulfate-induced colitis via prostaglandin D2-mediated D prostanoid receptor 1 activation¹⁹. In 78 addition, niacin serves as a precursor for coenzymes, such as nicotinamide adenine dinucleotide 79 (NAD) and nicotinamide adenine dinucleotide phosphate (NADP), which are essential for the 80 normal function and survival of living cells. However, a mechanistic role for malnutrition in 81 driving EED pathophysiology in humans remains to be demonstrated. 82 Studying a multifactorial disease, such as EED, raises substantial methodical and 83 modeling challenges and, at present, there are only a few murine models and no existing 84 human *in vitro* models that can be used to study this disease²⁰. Thus, establishing an *in vitro* 85 human EED model would help to elucidate disease pathophysiology and enable the 86 development of new prevention and therapeutic measures. Here, we describe how human 87 organ-on-a-chip (Organ Chip) microfluidic culture technology that faithfully recapitulates the 88 structure and function of many human organs, including intestine²¹⁻³⁰, can be leveraged to 89 meet this challenge. Our studies using human Intestine Chips lined with organoid-derived 90 primary intestinal epithelium isolated from either healthy or EED patients presented here 91 reveal that both nutritional deficiencies and genetic or epigenetic changes in the intestinal 92 epithelium contribute to the clinically observed EED phenotype. Moreover, by comparing 93 healthy and EED patient-derived Intestine Chips, we were able to study phenotypic responses 94 to nutritional deficiencies, such as villus blunting and barrier dysfunction, which are known to 95 be common to multiple intestinal pathologies (for example, inflammatory bowel diseases,

96 celiac), and which distinguish them from responses due to transcriptomic and cytokine

- 97 signatures that are unique to EED.
- 98
- 99 **RESULTS**

100 Nutritionally deficient EED Chips recapitulate EED patient transcriptional signatures

101 We previously described a two-channel, microfluidic, human Intestine Chip lined with 102 living human intestinal epithelium isolated from patient-derived organoids that undergoes villus 103 differentiation, accumulates mucus, and exhibits many features of living human intestine when 104 cultured on-chip under continuous flow with peristalsis-like mechanical deformations²⁷ (Fig. 105 **1a**). Additionally, transcriptional analysis demonstrated that when lined by organoid-derived 106 duodenal epithelium, this Intestine Chip more closely mimicked *in vivo* human duodenum than 107 the organoids used to create the chips²⁷. To define the contribution of the intestinal epithelium 108 to the EED phenotype, we created Intestine Chips lined with intestinal epithelial cells from 109 organoids derived from surgical biopsies of either healthy or EED patient duodenum (Healthy 110 Chips and EED Chips, respectively). Compared to Healthy Chips, EED Chips showed differential 111 expression of 287 genes (FDR < 0.05 and fold change \geq 1.5; 86 upregulated, 201 112 downregulated) (Fig. 1b). EED chips showed upregulation of the protective mucin MUC5AC, 113 neuregulin-4 (a known survival factor for colonic epithelium that protects against experimental 114 intestinal injury^{31,32}), and the intestinal stem cell marker SMOC2, whereas brush border 115 peptidase MME, oxidative stress and inflammatory response controlling ectoenzyme VNN1, 116 tight junction protein CLDN10, and secreted goblet cell protein CLCA1 were all down-regulated 117 (Supplementary Table 1).

118 We compared this differential gene expression profile with a recently derived clinical 119 EED signature, which was obtained by comparing profiles of intestinal tissue samples from EED 120 patients who were refractory to nutritional intervention (Study of Environmental Enteropathy 121 and Malnutrition, SEEM) versus samples from healthy control patients who were investigated 122 for gastrointestinal symptoms but had normal endoscopic and histologic findings (Cincinnati 123 Children's Hospital Medical Center)³³. When we compared gene profiles from EED Chips versus 124 Healthy Chips cultured in control medium (i.e., with all nutrients present), the differentially 125 expressed genes had some overlap with the clinical EED signature, including most notably a 126 shared downregulation of metallothioneins (MT1X, MT1A, MT1F, MT1H, MSMB, MT1M; gene 127 dendrogram cluster 3) (Fig. 1c).

128 We then carried out the same experiment but perfused both the Healthy and EED 129 Intestine Chips with medium deficient in niacinamide and tryptophan (-N/-T), selected based on 130 past work implicating their role in EED^{15,16,19}. When we compared expression profiles from the 131 Healthy Chips exposed to nutritional deficiency (Healthy -N/-T Chip) versus the Healthy Control 132 Chips, we detected differential expression of 690 genes (FDR < 0.05 and fold change \geq 1.5; 556 133 upregulated, 124 downregulated) (Fig. 1b and Supplementary Fig.S1) including upregulation of 134 the amino acid starvation related transcription factor ATF4, its downstream solute carriers 135 (SLC34A2, SLC7A5, SLC6A9) and the inflammation-associated gene LCN2 (Supplementary Table 136 **1**). There also appeared to be a trend towards upregulation of several antimicrobial and 137 immune response genes as seen in the clinical EED signature, but these changes did not reach 138 statistical significance. While there was greater overlap between the transcriptome of the 139 Healthy -N/-T Chip with the clinical EED transcriptome than observed with the EED Control Chip

140	compared to Healthy Control Chip, some genes were regulated in an opposing
141	direction, including upregulation of metallothioneins (Fig. 1c, gene dendrogram cluster 3).
142	In contrast, we observed closer unsupervised hierarchical clustering with the clinical EED
143	signature when the EED Chip was exposed to nutritional deficiency (EED -N/-T Chip vs EED
144	Control Chip) (Fig. 1c). Culture of the EED Intestine Chips in -N/-T medium yielded differential
145	expression of 969 genes (FDR < 0.05 and fold change \geq 1.5; 522 upregulated, 447
146	downregulated) (Fig. 1b). This was manifested by upregulation of antimicrobial genes (SAA1,
147	SAA2, DUOXA2, DUOX2, CXCL5; gene dendrogram clusters 8, 9 and 10) and downregulation of
148	not only metallothioneins, but also metabolic and digestive genes (SLC26A3, GUC2AB; gene
149	dendrogram clusters 5 and 6). This congruence was most striking amongst the top ten
150	upregulated genes of the clinical EED signature, 6 of which (60%) were also upregulated when
151	EED Chips were exposed to nutritionally deficient medium (Fig. 1d). Dendrogram cluster 5 was
152	largely incongruent with the Intestine Chip transcriptional signature and included genes
153	predominantly expressed in nerves, muscle and extracellular matrix.
154	To identify pathways affected by exposure of EED Intestine Chips to -N/-T nutritional
155	deficiency, we used a contextual language-processing program to identify and rank functionally
156	related clusters of genes ³⁴ . This analysis revealed several pathways that were significantly
157	upregulated when EED Chips were exposed to -N/-T media, including chemokine pathway
158	(score 1833.89, indicates fold enrichment over random association) and pathway associated
159	with amino acid starvation (score 1988.09) (Fig. 1e). Within the amino acid starvation pathway,
160	the ATF4 gene is upstream of several other pathways including tRNA metabolism (score
161	1547.01), DNA damage (score 1790.28), p53 methylation (score 1608.44), and amino acid

162	transporters (score 2022.97). Many of these same pathways were also upregulated in
163	nutritionally deficient Healthy -N/-T Chips. Conversely, nutritional deficiency led to down
164	regulation of pathways related to fatty acid uptake (score 3590.64), brush border structural
165	integrity (score 3777.69), mitosis (score 3311.49), cytochrome p450 (score 2581.54), and fatty
166	acid utilization (score 2056.86) in the EED Chips. These results are consistent with the
167	observation that the intestines of nutritionally deficient EED patients are characterized by
168	having decreased brush border development and impaired cell growth ³⁵⁻³⁷ .
169	Intestinal villus atrophy and barrier compromise
170	As the transcriptomic analysis revealed downregulation in pathways involved in cell
171	growth and intestinal barrier formation, we carried out differential interference (DIC) and

172 immunofluorescence microscopic analysis which indeed confirmed that both Healthy and EED

173 Intestine Chips showed dramatically reduced growth of villus-like structures when cultured

174 under nutrition deficient (-N/-T) conditions compared to Health and EED Control Chips perfused

175 with complete medium (**Fig. 2a,b**). Quantification of the height of the epithelium revealed that

176 removal of these nutrients resulted in significant villus blunting in both Healthy and EED Chips

177 in response to -N/-T deficiency, as indicated by a 70% and 80% reduction in epithelial height,

178 respectively, when compared to the same chips cultured in complete medium (**Fig. 2c**).

Another gene cluster identified as being preferentially sensitive to nutritional deficiency includes genes governing brush border structural integrity. These genes included myosin 1a (MYO1A), which links actin to the overlying apical membrane and whose absence results in irregularities of microvilli packing and length ³⁸; protocadherin-24 (CDHR2) that forms links between adjacent microvilli and is the target of enterohemorrhagic *Escherichia coli*-mediated

184	brush border damage ³⁹ ; and mucin-like protocadherin (CDHR5) that forms heterophilic
185	complexes with CDHR2 (Supplementary Fig. S2). Indeed, scanning electron microscopic (SEM)
186	imaging revealed that culturing healthy intestinal epithelium in -N/-T medium on-chip resulted
187	in severe loss of apical microvilli (as well as links between adjacent microvilli) relative to control
188	enterocytes that had their entire surface covered with tightly packed microvilli (Supplementary
189	Fig. S3). Consistent with these findings and the observed down regulation of the MUC5AC gene,
190	live imaging and mucus staining with fluorescent lectin revealed that both the Healthy and EED
191	Chips exhibited a much thinner mucus layer when exposed to nutrient deficient conditions (Fig.
192	2d).
193	Following these observations of structural changes due to exposure to nutritional
194	deficiency, we next leveraged the advantage of using a two-channel microfluidic Intestine Chip
195	(Fig. 1a) (e.g., as opposed to intestinal organoids cultured within a solid ECM gel) to assess the
196	effect of exposure to -N/-T medium on functional differences in intestinal barrier function
197	between Healthy and EED Chips. We compared apparent permeability (P_{app}) values, which were
198	measured by calculating the transfer of Cascade Blue fluorescent tracer (~550 Da) from the
199	epithelial lumen in the top channel to the underlying parallel channel below. Both Healthy and
200	EED Control Chips exhibited a tight barrier under baseline conditions (within the $10^{-7} P_{app}$ range)
201	and displayed small, but statistically significant reductions in barrier function when exposed to
202	nutritional deficiency, as indicated by 8.9- and 2.5-fold increases in P_{app} for the Healthy and EED
203	Chips, respectively (Fig. 2e).
204	

206 **Reduced nutrient absorption**

207 Our transcriptomic analysis also revealed that nutritional deficiency resulted in down 208 regulation of multiple genes associated with the uptake and processing of important nutritional 209 components, including fatty acids, certain amino acids, and carbohydrates (Fig. 1d). This is 210 clinically relevant because reduced absorption of nutrients is another hallmark of EED, and it 211 affects weight and linear growth as well as cognitive development in children⁴⁰⁻⁴³. For example, 212 expression levels for fatty acid translocase (CD36), microsomal triglyceride transfer protein 213 (MTTP), apolipoprotein B (ApoB), and apolipoprotein C-III (ApoC3) were all lower in nutritionally 214 deficient epithelium (Fig. 3a). Similarly, when we used immunofluorescence microscopy to 215 assess expression of ApoB protein, which is a marker of chylomicron and fat metabolism in the 216 intestine ⁴⁴, we found that exposure to -N/-T nutritional deficiency resulted in significant down 217 regulation of ApoB in EED Intestine Chips (Fig. 3b). Furthermore, when we quantified cellular 218 uptake of fatty acids using fluorescently-labelled dodecanoic acid, we found that exposure to 219 nutritional deficiency reduced fatty acid uptake by 1.68- and 1.69-fold in Healthy -N/-T Chips 220 and EED -N/-T Chips, respectively, compared to Healthy and EED Control Chips (Fig. 3c). These 221 findings are consistent with clinical data that similarly show impaired fatty acid metabolism in 222 children suffering from EED¹⁶ and suggest that nutritional deficiency alone is sufficient to 223 reduce fatty acid uptake even in healthy intestine.

224 Abnormal amino acid uptake and metabolism

225 Children suffering from EED exhibit impaired development, and protein availability from 226 the diet is a key factor responsible for linear growth; thus, we next explored differences in 227 uptake by Healthy and EED Intestine Chips. In the intestine, dietary protein is broken down into

228	short peptides and free amino acids that are taken up by enterocytes, which serve as building
229	blocks and energy sources for various organs and tissues ⁴⁰ . Transcriptomic analysis revealed
230	absorption and metabolizing factors that were down regulated in EED Control Chips vs Healthy
231	Control Chips, including the solute carrier family 2 (facilitated glucose transporter) member 2
232	(SLC2A2) and solute carrier family 2 (facilitated glucose/fructose transporter) member 5
233	(SLC2A5). Other nutrient transporters (e.g., amino acid absorption and metabolizing factors)
234	that were found to be significantly down regulated in EED Chips in response to -N/-T deficiency
235	(EED -N/-T vs EED Con), include SLC36A1, which encodes the proton-coupled amino acid
236	transporter 1, ANPEP membrane enzyme alanyl aminopeptidase that is responsible for peptide
237	digestion at the brush border, retinol binding protein 2 (RBP2), cytochrome P450, family 27,
238	subfamily A, and polypeptide 1 (CYP27A1) (Fig. 4a and Supplementary Fig. S4).
239	We then assessed differences in absorption of nutrients between the Healthy and EED
239 240	We then assessed differences in absorption of nutrients between the Healthy and EED Intestine Chips grown in control medium by performing untargeted metabolomic analysis by
240	Intestine Chips grown in control medium by performing untargeted metabolomic analysis by
240 241	Intestine Chips grown in control medium by performing untargeted metabolomic analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) to analyze epithelial uptake of
240 241 242	Intestine Chips grown in control medium by performing untargeted metabolomic analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) to analyze epithelial uptake of nutrients and transfer of these molecules from the lumen of the intestinal epithelium in the top
240241242243	Intestine Chips grown in control medium by performing untargeted metabolomic analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) to analyze epithelial uptake of nutrients and transfer of these molecules from the lumen of the intestinal epithelium in the top channel to the underlying basal channel (Fig. 1a). We detected 36 metabolites (out of >500
 240 241 242 243 244 	Intestine Chips grown in control medium by performing untargeted metabolomic analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) to analyze epithelial uptake of nutrients and transfer of these molecules from the lumen of the intestinal epithelium in the top channel to the underlying basal channel (Fig. 1a). We detected 36 metabolites (out of >500 identified) that exhibited lower transport in EED Intestine Chips compared to Healthy Chips
 240 241 242 243 244 245 	Intestine Chips grown in control medium by performing untargeted metabolomic analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) to analyze epithelial uptake of nutrients and transfer of these molecules from the lumen of the intestinal epithelium in the top channel to the underlying basal channel (Fig. 1a). We detected 36 metabolites (out of >500 identified) that exhibited lower transport in EED Intestine Chips compared to Healthy Chips grown in control medium. These included mainly amino acids metabolites, but also metabolites
 240 241 242 243 244 245 246 	Intestine Chips grown in control medium by performing untargeted metabolomic analysis by liquid chromatography tandem mass spectrometry (LC-MS/MS) to analyze epithelial uptake of nutrients and transfer of these molecules from the lumen of the intestinal epithelium in the top channel to the underlying basal channel (Fig. 1a). We detected 36 metabolites (out of >500 identified) that exhibited lower transport in EED Intestine Chips compared to Healthy Chips grown in control medium. These included mainly amino acids metabolites, but also metabolites related to nucleotide, cofactors, lipids, carbohydrates and xenobiotic pathways (Fig. 4b ; an

250 methionine, phenylalanine, lysine), conditionally essential amino acids (arginine, glycine), and
251 non-essential amino acids (glutamate, serine).

252	Our LC-MS/MS analysis also revealed 74 metabolites that were secreted by the
253	intestinal cells as they were absent or at extremely low levels (<5%) in the perfusion medium.
254	17 of these metabolites were unique to the Healthy Control Chips and included products of
255	pathways related to metabolism of amino acids (N6,N6,N6-trimethyllysine, 3-
256	hydroxyisobutyrate, methionine sulfone, N-acetylglutamine, homoarginine, indolelactate,
257	glutamine, alanine, betaine, imidazole lactate, 3-methylhistidine, 1-methylhistidine),
258	nucleotides (thymine, 2'-deoxyuridine, 7-methylguanine), xenobiotic metabolism (guaiacol
259	sulfate), or lipids (3-hydroxy-3-methylglutarate). Interestingly, we also identified 4 metabolites
260	unique to the EED Chips cultured in control medium, including products of purine nucleotide
261	metabolism (xanthine), vitamin B6 metabolism (pyridoxal), citric acid cycle /energy metabolism
262	(alpha-ketoglutarate), and fatty acid metabolism (acetylcarnitine (C2)) (Fig. 4c).
263	To assess if the observed differential uptake and metabolism of molecules in the
264	Intestine Chips were transporter dependent, we quantified uptake of the dipeptide, glycyl-
265	sarcosine (Gly-Sar) by the epithelial cells in the top channel, and its transfer to the lower
266	channel using LC-MS/MS. This analysis revealed reduced uptake and transport of Gly-Sar in
267	nutritionally deficient Healthy Intestine Chips when compared to the same chips cultured in
268	control medium (Supplementary Fig. S5). In addition, these studies confirmed that these
269	effects were due to transport through the PEPT1 transporter, and not due to passive inter- or
270	intra-cellular diffusion, as this response could be completely prevented by adding Gly-Gly
271	dipeptide (1 mM), which is a specific inhibitor of this transporter ⁴⁶ (Supplementary Fig. S5).

272 Altered inflammatory mediators

273	Altered intestinal inflammation is a key component of EED and our transcriptional
274	analysis revealed that genes encoding key inflammatory marker proteins, such as lipocalin 2
275	(LCN2) and regenerating islet-derived protein 3 alpha (REG3A) were upregulated when EED or
276	Healthy Chips were exposed to nutritional deficiency (Fig. 1c and Supplementary Fig. S7).
277	Indeed, when we quantified the expression of nine key intestinal cytokines using a multiplexed
278	ELISA assay, we detected higher levels of several cytokines (IL-6, ICAM, VCAM, IL-33, MCP-1,
279	MIP-1 alpha and IL-8) in the epithelial lumen of Healthy -N/-T Intestine Chips compared to the
280	same chips cultured in control medium (Fig. 5a). The antimicrobial peptide Reg3A was also
281	downregulated by nutritional deficiency in these chips. Interestingly, EED Intestine Chips grown
282	in complete medium displayed reduced levels of all of the secreted cytokines analyzed, while
283	their levels were significantly upregulated when these chips were grown in nutritionally
284	deficient medium (Fig. 5a). Similar responses were observed when we analyzed cytokine levels
285	in the lower parenchymal or vascular channel; however, there significantly higher levels of the
286	inflammatory cytokines IL-8, IP-10, and MCP-1 were observed (Fig. 5a). Interestingly, we found
287	that Intestine Chips that were not exposed to mechincal peristalsis-like deformation, secreted
288	lower levels of IL-8 and MCP-1 (Supplementary Fig. S8).
200	

289

290 **DISCUSSION**

Given the importance of studying the pathophysiology and the underlying mechanisms of EED, and the current lack of human *in vitro* models, this study leveraged the Human Intestine Chip technology to create an in vitro EED model using cells obtained from EED and healthy 294 patient intestinal biopsies. The Intestine Chip offers a unique advantage over other advanced in 295 vitro models, such as intestinal organoids, because direct access to the two parallel flow 296 channels of the device enable quantitation of intestinal barrier function as well as 297 transepithelial absorption and transport that are not possible in static 3D enteroid cultures. 298 Using this approach, we explored the effect of nutritional deficiencies on the manifestation of 299 the disease at both the phenotypic and functional levels. Importantly, our results showed that 300 human Intestine Chips lined by intestinal epithelial cells isolated from organoids derived from 301 EED patients mimic key features of the transcriptome signature of EED patients, including 302 upregulation of antimicrobial genes and downregulation of metallothioneins and genes involved 303 in digestion and metabolism, but only when exposed to nutritional deficiency, which we 304 modeled by removing niacin and tryptophan from the medium. In contrast, nutritional 305 deficiency induced similar intestinal villus atrophy, disruption of barrier function, and changes in 306 amino acid and fatty acid absorption in chips lined by cells from both healthy and EED patients. 307 Thus, we were able to attribute these various responses specifically to nutritional deficiency, to 308 genetic or epigenetic changes in the intestinal epithelium, or to a combination of both, 309 distinctions that have not been possible to make in clinical studies. 310 Malnutrition in EED can be regarded as both a cause and an outcome of the disease. In 311 this study, we examined the effect of dual deficiency of an essential amino acid tryptophan and 312 the vitamin niacin (in the form of niacinamide) because of their reported effect on intestinal 313 development and function, and the suggested correlation between their deficiencies and EED 314 development^{45,47}. Remarkably, we observed a 6-fold increase in number of genes differentially 315 expressed when we compared the EED Intestine Chips exposed to nutritional deficiency

compared to Healthy Chips grown in complete medium. Moreover, many of the affected
 pathways were associated with nutritional uptake and cellular energy processing. These results
 imply that nutritional deficiency itself leads to derangements in nutritional processing that
 create a positive feedback loop, which further worsens the nutritional deficiency in EED
 patients.

321 Villus blunting and barrier dysfunction are hallmarks of EED, but also of other intestinal 322 pathological conditions, such as inflammatory bowel diseases, celiac, diarrhea and small 323 intestine bacterial overgrowth^{48,49}. Indeed, we were able to show in this study that these 324 phenotypes can manifest because of nutritional deficiencies regardless of whether the 325 intestinal epithelium was derived from healthy or EED patients. This implies that the villus 326 blunting and barrier dysfunction observed in EED, may be a response to environmental 327 conditions, rather than an inherent genetic or developmental feature of this disease. This 328 finding has high clinical relevance because the intestinal epithelium undergoes continuous 329 shedding and renewal every 3-5 days; hence, the chronic negative effect of nutritional 330 deficiencies might explain a fundamental aspect of the malabsorption and poor response to 331 oral vaccination seen in EED patients. The ability to dissect and assess the factors leading to 332 villus blunting in EED (as well as in other intestinal conditions) in vitro is a unique capability 333 enabled by Intestine Chips that support formation of 3D villus-like structures as well as mucus 334 production and quantification of transepithelial transport, absorption, and secretion. 335 Fat is a macronutrient responsible for 30 to 40% of total caloric intake in children and 20

to 35% in adults, and fatty acid composition has a direct effect on health and development,

337 including inflammatory status and cognitive development.^{50,51} Our transcriptomic analysis was

sensitive enough to detect several genes including ApoB that were downregulated in
nutritionally deficient epithelium, and we confirmed that the expression of this molecule is
decreased using immunofluorescence microscopy, and that fatty acid absorption is impaired in
both EED -N/-T and Healthy -N/-T Chips (when compared to their respective controls), using a
fatty acid uptake assay.

343 Given that dietary protein is an important macronutrient directly linked to linear growth 344 and the results from our transcriptome-wide analysis revealed downregulation of amino acid 345 transporters in EED Chips, we also conducted a untargeted metabolomic analysis that identified 346 several amino acids which are significantly reduced in the EED Control Chips when compared to 347 Healthy Control Chips. More interestingly, we identified metabolites that were secreted by the 348 intestinal epithelium into the lower channel. Thus, the Intestine chip may be used as a 349 nutritional and metabolic screening tool where uptake, utilization, and secretion of specific 350 metabolites by and through the intestinal epithelium can be followed in high resolution and 351 quantified over time. Moreover, future analysis of molecules released into the lower flow 352 channel could lead to identification of biomarkers of disease severity and/or progression that 353 might be detectable in blood.

While reduction of intestinal absorptive surface area due to villus blunting caused by nutritional deficiency will impair nutrient uptake by the intestine, exposure to nutritional deficiency also directly suppressed expression of multiple genes related to nutrient absorption specifically in chips lined by cells from EED patients. Thus, these results suggest that nutritional deficiency has a two-fold effect in these patients, which would likely manifest in a greater degree of intestinal dysfunction and a more severe EED phenotype. In our study, we also found 360 that EED Intestine Chips exposed to nutritional deficiencies produced greater amounts of 361 inflammatory cytokines compared to Healthy Chips grown under the same -N/-T conditions. 362 This is a critical detail as inflamed intestine has higher caloric demands for basic maintenance 363 and renewal, which could result in a negative caloric balance unable to support catch-up 364 growth. Furthermore, chronic inflammation may negatively affect the efficacy of oral vaccines 365 in the EED intestine. As such, it is possible that the lack of catch-up growth in EED children 366 receiving nutritional intervention is due to current interventions only supplying nutrients aimed 367 at replenishing the deficiency in tissues responsible for linear growth (bone, muscles). A more 368 effective approach might be to first administer a diet composition that preferentially promotes 369 intestinal recovery with new formation of villi and restores increased intestinal absorptive area 370 before moving to supplementation required for catch-up growth.

371 The unique ability of the Intestine Chips to allow environmental factors (e.g., cell source, 372 nutrient levels) individually or in combination in a controlle manner and to explore multiple 373 clinically relevant outcomes, such as cell and tissue morphology, barrier function, nutrients 374 metabolism and absorption, inflammatory status and transcriptome modifications, enabled us 375 to distinguish between manifestations more common to multiple intestinal diseases versus 376 responses that are more unique to EED. For example, we identified the cluster of differentiation 377 36 (CD36), gene, which has several functions relevant to EED as well as intestinal cancer and 378 other intestinal diseases (e.g., fatty acid translocase, regulator of inflammation, oxidative stress, 379 angiogenesis) to be significantly down regulated under nutritional deficiencies in both Healthy 380 and EED Intestine Chips. Remarkably, our findings relating to EED are directly in line with 381 recently published clinical data that explored unique signatures of EED affected children

compared to healthy controls and children with celiac disease³³. Thus, this *in vitro* EED model
 may be useful for gaining further insight into the pathophysiology of this disease as well as for
 development of potent therapeutics. The Intestine Chip also could provide a platform for
 personalized medicine and nutrition when cultured with clinical biopsies, enabling personalized
 (patient-specific) digestion, absorption, and allergic reactions to be assessed for different
 nutrients without putting the patient in danger.

388

389 METHODS

390 Organoid cultures and Intestine Chips

391 Organoids from Healthy donors or EED patients were generated from biopsy samples 392 collected during exploratory gastroscopy following a procedure previously described⁵². A total 393 of 3 Healthy and 2 EED donors were used to generate the data in this study (Supplementary 394 Table 2). For the Healthy Chips, de-identified endoscopic tissue biopsies were collected from 395 grossly unaffected (macroscopically normal) areas of the duodenum in patients undergoing 396 endoscopy for gastrointestinal complaints. Informed consent was obtained at Boston Children's 397 Hospital from the donors' guardian. All methods were carried out in accordance with the 398 Institutional Review Board of Boston Children's Hospital (Protocol number IRB-P00000529) 399 approval. For the EED Chips, de-identified endoscopic tissue biopsies were collected from 400 affected areas of the duodenum in patients undergoing endoscopy following unsuccessful 401 educational and nutritional intervention for wasting. Informed consent was obtained at the 402 household level in a rural district of Matiari, Sind, Pakistan from the donors' guardians. All 403 methods were carried out in accordance with the AKU Ethical Review Committee's approval

404 (ERC number 3836-Ped-ERC-15). Organoids were kept in complete growth medium^{27,52}, and 405 passaged every 7 days in a 1:4 ratio. Before cell seeding, S-1 Chips (Emulate) were activated 406 using ER1/2 (Emulate) and UV exposure for 20 minutes. Chips were then coated with 200 μ g 407 ml⁻¹ collagen I (BD Corning) and 100 µg ml⁻¹ Matrigel (BD Corning) in serum-free DMEM-F12 408 (Gibco) for 2 hours at 37 °C. After wash, organoids were broken into smaller fragments using 409 enzymatic activity (TryplE, Gibco) and seeded in the luminal upper channel of the chips. They 410 were then allowed to adhere for 24h before introduction of flow and mechanical deformation 411 as described before²⁷. For the -N/-T treatment, niacinamide and tryptophan were removed 412 from the basal medium (DMEM-F12, Gibco) used to prepare the expansion culture medium 413 (used for the luminal and lower channels) and no additional niacinamide was added²⁷. After 16-414 18 days in culture with continuous flow (60 μ l/h) and mechanical deformation (10%, 0.15 Hz), 415 medium was changed to differentiation medium (serum and Wnt-3A free²⁷, and -N/-T free for 416 the respective group), in the luminal top channel and expansion culture medium in the lower 417 channel for 4 additional days.

418 Microarray sequencing and bioinformatics analysis

Initial microarray experiments were carried out using one healthy donor (n=3 biological
replicates) and one EED donor (n=3 biological replicates) and were reflective of a recent clinical
EED transcriptomic signature derived from a larger population (SEEM study, n=25 healthy
donors, 52 EED donors). Subsequent validation studies were carried out using 1-3 healthy
donors (n=3-9 biological replicates) and 1-2 EED donors (n=3-8 biological replicates) per
experiment. RNA samples were processed using the GeneChip WT PLUS Reagent Kit and
hybridized to Affymetrix Human Clariom D arrays. Samples were pre-processed with SCAN

426	(SCAN.UPC package) and resulting expression values were quantile-normalized within the
427	experiment, and differential expression analysis was performed with limma ⁵³ R package for
428	each comparison pair; gene expression values were averaged for each condition. Template
429	matching was used to extract genes that are differentially expressed between these conditions.
430	Differential gene expression heatmap analysis was preformed using Euclidean distance and
431	McQuitty's linkage within the R package heatmaply ³⁴ . To normalize values across experiments,
432	columns were scaled to generate a Z-score. Pathway analysis was performed using the natural
433	language processing algorithm COmprehensive Multi-omics Platform for Biological
434	InterpretatiOn (COMPBIO) to generate a holistic, contextual map of the core biological themes
435	associated with gene expression changes. Enriched concepts associated with differentially
436	expressed genes were compiled from PubMed abstracts using contextual language processing.
437	Themes were scored using a complex function that incorporates an empirical p value and a
438	standard score similar to a Z-score to give a final value representing fold enrichment over a
439	random clustering as follows: 3-9 = weak relationship, 10-99 = modest relationship, 100-999 =
440	strong relationship, 1000+ = very strong relationship. A theme map was generated where
441	themes are represented as nodes and interconnections between themes are represented as
442	edges with the thickness of an edge relating to the degree of interconnection.

_

443 *Immunofluorescence microscopy*

Immunofluorescence microscopic imaging was carried out using the following steps: the
apical and basal channels of the chips were gently washed with PBS and fixed with 4%
paraformaldehyde (Electron Microscopy Sciences, Cat#: 157-4) in PBS for 30 min, then washed
twice with PBS and kept at 4°C. The fixed samples were sectioned to 150-250 µm sections using
a vibratome (Leica), and then permeabilized and blocked with 0.1% Triton X-100 solution and

449 10% Donkey serum in PBS, for 30 min at room temperature. Then primary antibody (Apo-B, 450 Abcam, Cat#:ab20737) was added (1:100 in 1.5% BSA/PBS solution) and incubated overnight at 451 4 °C, followed by multiple PBS washes. Cells were then incubated with secondary fluorescent 452 antibody (Invitrogen Cat#:SA5-10038) and Phalloidin (Invitrogen Cat#: A12380) at room 453 temperature for 60 min and washed with PBS; nuclei were co-stained with hoechst 33342 454 (Sigma, Cat#: 14533). Microscopy was performed with a laser scanning confocal microscope (Leica SP5 X MP DMI-6000 or Zeiss TIRF/LSM 710). 455 456 457 Paracellular permeability measurements

458 To assess paracellular permeability, 50 µg ml⁻¹ of Cascade blue (5.9 kDa; Thermo Fisher, 459 C687) was introduced to the luminal channel (at 60 ml h^{-1}). After flowing over-night to saturate 460 the microfluidic channels, outflows were discarded and collection for measurements started for ~24 hours. The fluorescence intensities (390nm/420nm) of the top and bottom channel 461 462 effluents were measured using a multimode plate reader (BioTek NEO). The apical to-463 basolateral flux of the paracellular marker was calculated using the following equation: 464 Papp=(dQ/dt)/AdC. dQ/dt (g s⁻¹) is molecular flux, A (cm²) is the total area of diffusion and dC 465 (mg ml⁻¹) is the average gradient.

466 *Mucus assessment*

Mucus was visualized using a WGA–Alexa Fluor 488 conjugate (Thermo Fisher Scientific,
Cat#: W11261) for live cell imaging, as described previously²⁵ with some modifications. Briefly
WGA solution (25 μg ml⁻¹ in HBSS) was flowed through the epithelium channel for 30 minutes
and then washed with continuous flow of HBSS for 30 min. Intestine chips were then cut
sideways parallel to the length of the channel and imaged with an epifluorescence microscope
(Zeiss Axio Observer Z1) with 5x objective.

473 Fatty Acid Uptake

474 Chips were starved for 1 hour by replacing the luminal and lower channel media with
475 HBSS. Then, fluorescently-labelled dodecanoic acid combined with a quencher (to eliminate any
476 unspecific signal), were added according to the manufacturer instructions (BioVision, Cat#:
477 K408) to the luminal upper channel of the intestine chips. The entire length of the channels was
478 then imaged with an epifluorescence microscope (Ex/Em = 488/523 nm, Zeiss Axio Observer Z1)
479 with 5x objective, at 5, 10, 30 and 60 minutes.
480 *Metabolomics*

481 Medium in the lower channel of the chips was changed to HBSS and flowed for 30 482 minutes to clear any residues. Then collection of outflows was conducted over 5 hours. Samples 483 were frozen immediately after collection (-80 °C), and submitted for LC-MS/MS analysis. The 484 Metabolon global metabolomics platform was used to measure biochemicals in cell and media 485 samples. Samples were prepared using the automated MicroLab STAR[®] system from Hamilton 486 Company. Several recovery standards were added prior to the first step in the extraction 487 process for QC purposes. To remove protein, dissociate small molecules bound to protein or 488 trapped in the precipitated protein matrix, and to recover chemically diverse metabolites, 489 proteins were precipitated with methanol under vigorous shaking for 2 min (Glen Mills 490 GenoGrinder 2000) followed by centrifugation. The resulting extract was divided into five 491 fractions: two for analysis by two separate reverse phase (RP)/UPLC-MS/MS methods with 492 positive ion mode electrospray ionization (ESI), one for analysis by RP/UPLC-MS/MS with 493 negative ion mode ESI, one for analysis by HILIC/UPLC-MS/MS with negative ion mode ESI, and 494 one sample was reserved for backup. Samples were placed briefly on a TurboVap[®] (Zymark) to

495 remove the organic solvent. Raw data was extracted, peak-identified and QC processed using
496 Metabolon's hardware and software.

497	Beginning with the OrigScale values from Metabolon, which are normalized in terms of
498	raw area counts, we calculated total ion count in outflow to visualize sample-wise variance.
499	Next, we normalized each sample by its total ion count and rescaled each metabolite values by
500	dividing each metabolite by its root mean square. We visualized metabolite abundance using a
501	heatmap. Statistical analysis and heatmap generation was performed using R (R Foundation for
502	Statistical Computing, Vienna, Austria). We performed differential expression analysis by using
503	the limma ⁵³ R package (v3.32.10) was used to fit a linear model to the data. Log ₂ fold change, p -
504	value and adjusted <i>p</i> -value were calculated for each comparison using an unmoderated
505	Student's t-test and the FDR method for multiple testing correction ⁵⁴ . Adjusted p -values are
506	shown in the volcano plots. To assess transporter mediated uptake and transfer from the
507	luminal upper channel to the lower channel, glycyl-sarcosine (Gly-Sar, 1 mM, Sigma) alone or in
508	combination with the specific PEPT1 transporter inhibitor Gly-Gly dipeptide (1 mM, Sigma),
509	were added to luminal medium and their abundance in the lower channel outflow was
510	assessed.
511	Statistical analysis

512 Each Intestine Chip was used as a biological repeat for one terminal assay. Either a 513 Student's t-test or 2-way ANOVA was performed to determine statistical significance, as 514 indicated in the figure legends (error bars indicate standard error of the mean (SEM); *p*-values < 515 0.05 were considered to be significant).

517 **ACKNOWLEDGMENTS**

518	This research was sponsored by funding from the Bill and Melinda Gates Foundation
519	(independent support to D.E.I), NIH award DK119488 (to D.T.B), and the Wyss Institute for
520	Biologically Inspired Engineering (to D.E.I). This work was conducted with the support of a KL2
521	award (an appointed KL2 award) from Harvard Catalyst The Harvard Clinical and Translational
522	Science Center (National Center for Advancing Translational Sciences, National Institutes of
523	Health Award KL2 TR002542). The content is solely the responsibility of the authors and does
524	not necessarily represent the official views of Harvard Catalyst, Harvard University and its
525	affiliated academic healthcare centers, or the National Institutes of Health.
526	AUTHOR CONTRIBUTIONS
527	A.B, C.W.F, G.G and D.E.I. designed the research. A.B, C.W.F, B.S, W.C, A.N, N.L, S.S, S.K,
528	and S.J.F performed experiments. A.B, C.W.F, W.C, R.K.P, D.M.C, A.P, J.G, R.P.B, G.G and D.E.I.
529	analysed and interpreted the data. D.T.B. established and prepared human Healthy organoids.
530	J.I and A.A established and prepared human EED organoids. L.A.D and S.R.M provided the
531	clinical data. A.B, C.W.F and D.E.I. wrote the Article with input from G.G. All authors reviewed,
532	discussed and edited the manuscript.
533	COMPETING INTERESTS

534 D.E.I. holds equity in Emulate, Inc., consults for the company and chairs its scientific 535 advisory board.

536 DATA AVAILABILITY STATEMENT

537 Organ chip microarray data that support the findings of this study have been deposited

538 in Gene Expression Omnibus (GEO) with the accession codes to be determined prior to

539	public	ation. Clinical mRNASeq data referenced as a comparison are deposited in Gene
540	Expres	ssion Omnibus under accession number <u>GSE159495</u> . Unique biological materials used in
541	this st	udy are available from the corresponding author on reasonable request.
542		
543	REFER	RENCES
544	1	Kosek, M. et al. Assessment of environmental enteropathy in the MAL-ED cohort study:
545		theoretical and analytic framework. Clin Infect Dis 59 Suppl 4, S239-247, doi:10.1093/cid/ciu457
546		(2014).
547	2	Harper, K. M., Mutasa, M., Prendergast, A. J., Humphrey, J. & Manges, A. R. Environmental
548		enteric dysfunction pathways and child stunting: A systematic review. PLoS Negl Trop Dis 12,
549		e0006205, doi:10.1371/journal.pntd.0006205 (2018).
550	3	Yu, J. et al. Environmental Enteric Dysfunction Includes a Broad Spectrum of Inflammatory
551		Responses and Epithelial Repair Processes. Cell Mol Gastroenterol Hepatol 2, 158-174 e151,
552		doi:10.1016/j.jcmgh.2015.12.002 (2016).
553	4	Fahim, S. M., Das, S., Gazi, M. A., Mahfuz, M. & Ahmed, T. Association of intestinal pathogens
554		with faecal markers of environmental enteric dysfunction among slum-dwelling children in the
555		first 2 years of life in Bangladesh. Trop Med Int Health 23, 1242-1250, doi:10.1111/tmi.13141
556		(2018).
557	5	Oria, R. B. et al. Early-life enteric infections: relation between chronic systemic inflammation and
558		poor cognition in children. <i>Nutr Rev</i> 74 , 374-386, doi:10.1093/nutrit/nuw008 (2016).
559	6	Haghighi, P. & Wolf, P. L. Tropical sprue and subclinical enteropathy: a vision for the nineties.
560		Crit Rev Clin Lab Sci 34 , 313-341, doi:10.3109/10408369708998096 (1997).
561	7	Korpe, P. S. & Petri, W. A., Jr. Environmental enteropathy: critical implications of a poorly
562		understood condition. Trends Mol Med 18, 328-336, doi:10.1016/j.molmed.2012.04.007 (2012).
563	8	Crane, R. J., Jones, K. D. & Berkley, J. A. Environmental enteric dysfunction: an overview. Food
564		Nutr Bull 36 , S76-87, doi:10.1177/15648265150361S113 (2015).
565	9	Manary, M. J. et al. Perturbed zinc homeostasis in rural 3-5-y-old Malawian children is
566		associated with abnormalities in intestinal permeability attributed to tropical enteropathy.
567		Pediatr Res 67, 671-675, doi:10.1203/PDR.0b013e3181da44dc (2010).

568	10	Chen, P. et al. Association of vitamin A and zinc status with altered intestinal permeability:
569		analyses of cohort data from northeastern Brazil. J Health Popul Nutr 21 , 309-315 (2003).
570	11	van der Merwe, L. F. et al. Long-chain PUFA supplementation in rural African infants: a
571		randomized controlled trial of effects on gut integrity, growth, and cognitive development. Am J
572		<i>Clin Nutr</i> 97 , 45-57, doi:10.3945/ajcn.112.042267 (2013).
573	12	McKay, S., Gaudier, E., Campbell, D. I., Prentice, A. M. & Albers, R. Environmental enteropathy:
574		new targets for nutritional interventions. Int Health 2, 172-180, doi:10.1016/j.inhe.2010.07.006
575		(2010).
576	13	Louis-Auguste, J. et al. High dose multiple micronutrient supplementation improves villous
577		morphology in environmental enteropathy without HIV enteropathy: results from a double-blind
578		randomised placebo controlled trial in Zambian adults. BMC Gastroenterol 14, 15,
579		doi:10.1186/1471-230X-14-15 (2014).
580	14	Hashimoto, T. et al. ACE2 links amino acid malnutrition to microbial ecology and intestinal
581		inflammation. <i>Nature</i> 487 , 477-481, doi:10.1038/nature11228 (2012).
582	15	Guerrant, R. L. et al. Biomarkers of Environmental Enteropathy, Inflammation, Stunting, and
583		Impaired Growth in Children in Northeast Brazil. PLoS One 11, e0158772,
584		doi:10.1371/journal.pone.0158772 (2016).
585	16	Semba, R. D. et al. Environmental Enteric Dysfunction is Associated with Carnitine Deficiency
586		and Altered Fatty Acid Oxidation. EBioMedicine 17, 57-66, doi:10.1016/j.ebiom.2017.01.026
587		(2017).
588	17	Moehn, S., Pencharz, P. B. & Ball, R. O. Lessons learned regarding symptoms of tryptophan
589		deficiency and excess from animal requirement studies. J Nutr 142, 2231S-2235S,
590		doi:10.3945/jn.112.159061 (2012).
591	18	Council, N. R. in Recommended Dietary Allowances: 10th Edition The National Academies
592		Collection: Reports funded by National Institutes of Health (National Academies Press (US),
593		1989).
594	19	Li, J. et al. Niacin ameliorates ulcerative colitis via prostaglandin D2-mediated D prostanoid
595		receptor 1 activation. EMBO Mol Med 9, 571-588, doi:10.15252/emmm.201606987 (2017).
596	20	Brown, E. M. et al. Diet and specific microbial exposure trigger features of environmental
597		enteropathy in a novel murine model. <i>Nat Commun 6,</i> 7806, doi:10.1038/ncomms8806 (2015).


598	21	Herland, A. et al. Quantitative prediction of human pharmacokinetic responses to drugs via
599		fluidically coupled vascularized organ chips. Nat Biomed Eng 4, 421-436, doi:10.1038/s41551-
600		019-0498-9 (2020).
601	22	Chou, D. B. et al. On-chip recapitulation of clinical bone marrow toxicities and patient-specific
602		pathophysiology. Nat Biomed Eng 4, 394-406, doi:10.1038/s41551-019-0495-z (2020).
603	23	Park, T. E. et al. Hypoxia-enhanced Blood-Brain Barrier Chip recapitulates human barrier
604		function and shuttling of drugs and antibodies. Nat Commun 10, 2621, doi:10.1038/s41467-019-
605		10588-0 (2019).
606	24	Jang, K. J. et al. Reproducing human and cross-species drug toxicities using a Liver-Chip. Sci
607		Transl Med 11, doi:10.1126/scitranslmed.aax5516 (2019).
608	25	Jalili-Firoozinezhad, S. et al. A complex human gut microbiome cultured in an anaerobic
609		intestine-on-a-chip. <i>Nat Biomed Eng</i> 3 , 520-531, doi:10.1038/s41551-019-0397-0 (2019).
610	26	Musah, S., Dimitrakakis, N., Camacho, D. M., Church, G. M. & Ingber, D. E. Directed
611		differentiation of human induced pluripotent stem cells into mature kidney podocytes and
612		establishment of a Glomerulus Chip. Nat Protoc 13, 1662-1685, doi:10.1038/s41596-018-0007-8
613		(2018).
614	27	Kasendra, M. et al. Development of a primary human Small Intestine-on-a-Chip using biopsy-
615		derived organoids. <i>Sci Rep</i> 8 , 2871, doi:10.1038/s41598-018-21201-7 (2018).
616	28	Kim, H. J., Li, H., Collins, J. J. & Ingber, D. E. Contributions of microbiome and mechanical
617		deformation to intestinal bacterial overgrowth and inflammation in a human gut-on-a-chip. Proc
618		Natl Acad Sci U S A 113 , E7-15, doi:10.1073/pnas.1522193112 (2016).
619	29	Bhatia, S. N. & Ingber, D. E. Microfluidic organs-on-chips. Nat Biotechnol 32, 760-772,
620		doi:10.1038/nbt.2989 (2014).
621	30	Huh, D. et al. Reconstituting organ-level lung functions on a chip. Science 328, 1662-1668,
622		doi:10.1126/science.1188302 (2010).
623	31	McElroy, S. J. et al. The ErbB4 ligand neuregulin-4 protects against experimental necrotizing
624		enterocolitis. <i>Am J Pathol</i> 184 , 2768-2778, doi:10.1016/j.ajpath.2014.06.015 (2014).
625	32	Bernard, J. K., McCann, S. P., Bhardwaj, V., Washington, M. K. & Frey, M. R. Neuregulin-4 is a
626		survival factor for colon epithelial cells both in culture and in vivo. J Biol Chem 287, 39850-
627		39858, doi:10.1074/jbc.M112.400846 (2012).

628	33	Haberman, Y. et al. Mucosal Genomics Implicate Lymphocyte Activation and Lipid Metabolism in
629		Refractory Environmental Enteric Dysfunction. Gastroenterology 160, 2055-2071 e2050,
630		doi:10.1053/j.gastro.2021.01.221 (2021).
631	34	Galili, T., O'Callaghan, A., Sidi, J. & Sievert, C. heatmaply: an R package for creating interactive
632		cluster heatmaps for online publishing. Bioinformatics 34, 1600-1602,
633		doi:10.1093/bioinformatics/btx657 (2018).
634	35	Kelly, P. et al. Responses of small intestinal architecture and function over time to
635		environmental factors in a tropical population. Am J Trop Med Hyg 70, 412-419 (2004).
636	36	Campbell, D. I. et al. Chronic T cell-mediated enteropathy in rural west African children:
637		relationship with nutritional status and small bowel function. Pediatr Res 54, 306-311,
638		doi:10.1203/01.PDR.0000076666.16021.5E (2003).
639	37	Campbell, D. I., Elia, M. & Lunn, P. G. Growth faltering in rural Gambian infants is associated with
640		impaired small intestinal barrier function, leading to endotoxemia and systemic inflammation. J
641		<i>Nutr</i> 133 , 1332-1338, doi:10.1093/jn/133.5.1332 (2003).
642	38	Tyska, M. J. et al. Myosin-1a is critical for normal brush border structure and composition. Mol
643		<i>Biol Cell</i> 16 , 2443-2457, doi:10.1091/mbc.e04-12-1116 (2005).
644	39	In, J. et al. Enterohemorrhagic Escherichia coli reduce mucus and intermicrovillar bridges in
645		human stem cell-derived colonoids. Cell Mol Gastroenterol Hepatol 2, 48-62 e43,
646		doi:10.1016/j.jcmgh.2015.10.001 (2016).
647	40	Wu, G. Dietary protein intake and human health. <i>Food Funct</i> 7 , 1251-1265,
648		doi:10.1039/c5fo01530h (2016).
649	41	Nyaradi, A., Li, J., Hickling, S., Foster, J. & Oddy, W. H. The role of nutrition in children's
650		neurocognitive development, from pregnancy through childhood. <i>Front Hum Neurosci</i> 7 , 97,
651		doi:10.3389/fnhum.2013.00097 (2013).
652	42	Hurley, K. M., Yousafzai, A. K. & Lopez-Boo, F. Early Child Development and Nutrition: A Review
653		of the Benefits and Challenges of Implementing Integrated Interventions. Adv Nutr 7, 357-363,
654		doi:10.3945/an.115.010363 (2016).
655	43	Perkins, J. M., Subramanian, S. V., Davey Smith, G. & Ozaltin, E. Adult height, nutrition, and
656		population health. <i>Nutr Rev</i> 74 , 149-165, doi:10.1093/nutrit/nuv105 (2016).
657	44	Nakajima, K. et al. Apolipoprotein B-48: a unique marker of chylomicron metabolism. Adv Clin
658		Chem 64 , 117-177 (2014).

-0.57 45 Semba, N. D. et al. Child Standing is Associated with Low Circulating Essential Amino Acid.	659	45	Semba, R. D. et al. Child Stunting is Associated with Low Circulating Essential Amino Acids.
------------------------------------------------------------------------------------------------------	-----	----	----------------------------------------------------------------------------------------------


660 *EBioMedicine* **6**, 246-252, doi:10.1016/j.ebiom.2016.02.030 (2016).

- 46 Zietek, T., Rath, E., Haller, D. & Daniel, H. Intestinal organoids for assessing nutrient transport,
 662 sensing and incretin secretion. *Sci Rep* 5, 16831, doi:10.1038/srep16831 (2015).
- 663 47 Louis-Auguste, J. *et al.* Tryptophan, glutamine, leucine, and micronutrient supplementation
- 664 improves environmental enteropathy in Zambian adults: a randomized controlled trial. *Am J Clin* 665 *Nutr* 110, 1240-1252, doi:10.1093/ajcn/ngz189 (2019).
- 666 48 Elli, L. *et al.* Small bowel villous atrophy: celiac disease and beyond. *Expert Rev Gastroenterol*667 *Hepatol* 11, 125-138, doi:10.1080/17474124.2017.1274231 (2017).
- Antoni, L., Nuding, S., Wehkamp, J. & Stange, E. F. Intestinal barrier in inflammatory bowel
- 669 disease. World J Gastroenterol **20**, 1165-1179, doi:10.3748/wjg.v20.i5.1165 (2014).
- 50 Simopoulos, A. P. The importance of the ratio of omega-6/omega-3 essential fatty acids. *Biomed*671 *Pharmacother* 56, 365-379, doi:10.1016/s0753-3322(02)00253-6 (2002).
- 51 Stonehouse, W. Does consumption of LC omega-3 PUFA enhance cognitive performance in
- 673 healthy school-aged children and throughout adulthood? Evidence from clinical trials. *Nutrients*
- 674 **6**, 2730-2758, doi:10.3390/nu6072730 (2014).
- 675 52 Sato, T. *et al.* Long-term expansion of epithelial organoids from human colon, adenoma,
- adenocarcinoma, and Barrett's epithelium. *Gastroenterology* **141**, 1762-1772,
- 677 doi:10.1053/j.gastro.2011.07.050 (2011).
- 67853Ritchie, M. E. *et al.* limma powers differential expression analyses for RNA-sequencing and679microarray studies. *Nucleic Acids Res* **43**, e47, doi:10.1093/nar/gkv007 (2015).
- 680 54 Benjamini, Y. & Hochberg, Y. Controlling the False Discovery Rate: A Practical and Powerful
- 681 Approach to Multiple Testing. Journal of the Royal Statistical Society: Series B (Methodological)
- 682 **57**, 289-300, doi:<u>https://doi.org/10.1111/j.2517-6161.1995.tb02031.x</u> (1995).






EED -N/-T vs EED Con Functional Pathway Analysis




684

Figure 1. a) A schematic representation of Small Intestine chips. b) When compared to Healthy
Chips, the EED transcriptome consists of 287 differentially expressed genes (red; FDR < 0.05 and

687	fold change \geq 1.5). Exposure of Healthy and EED Chips to -N/-T media resulted in an increased
688	number of differentially expressed genes with 690 (yellow) and 969 genes (blue) respectively.
689	Of these 307 genes were differentially expressed in both Healthy and EED Chips exposed to
690	nutritional deficiency (yellow and blue). 71 genes were differentially expressed in EED Chips
691	when compared to Healthy Chips in control media that are further affected by the addition of
692	nutritionally deficient media (blue and red). n = 3 chips for each condition. c) A comparison of
693	the 50 most up- and 50 most downregulated genes from the clinical EED signature with Healthy
694	or EED Chip gene expression is depicted as a heatmap (red = upregulation, blue =
695	downregulation) showing that EED -N/-T has the closest hierarchical relationship to the clinical
696	EED signature. The comparison for EED -N/-T to Healthy Con is similar and shown in
697	Supplementary Fig. S9. Ten dendrogram gene clusters were also defined and the corresponding
697 698	Supplementary Fig. S9 . Ten dendrogram gene clusters were also defined and the corresponding roots enumerated. n = 3 chips for each condition. d) Of the top 9 upregulated genes in the
698	roots enumerated. n = 3 chips for each condition. d) Of the top 9 upregulated genes in the
698 699	roots enumerated. n = 3 chips for each condition. d) Of the top 9 upregulated genes in the clinical EED signature, 6 were also upregulated when EED chips were exposed to -N/-T media. n
698 699 700	roots enumerated. n = 3 chips for each condition. d) Of the top 9 upregulated genes in the clinical EED signature, 6 were also upregulated when EED chips were exposed to -N/-T media. n = 3 chips for each condition. e) Functional pathway analysis was performed using the
698 699 700 701	roots enumerated. n = 3 chips for each condition. d) Of the top 9 upregulated genes in the clinical EED signature, 6 were also upregulated when EED chips were exposed to -N/-T media. n = 3 chips for each condition. e) Functional pathway analysis was performed using the contextual language processing program COmprehensive Multi-omics Platform for Biological
698 699 700 701 702	roots enumerated. n = 3 chips for each condition. d) Of the top 9 upregulated genes in the clinical EED signature, 6 were also upregulated when EED chips were exposed to -N/-T media. n = 3 chips for each condition. e) Functional pathway analysis was performed using the contextual language processing program COmprehensive Multi-omics Platform for Biological InterpretatiOn (COMPBIO). The spatial map depicts themes related to differentially expressed
 698 699 700 701 702 703 	roots enumerated. n = 3 chips for each condition. d) Of the top 9 upregulated genes in the clinical EED signature, 6 were also upregulated when EED chips were exposed to -N/-T media. n = 3 chips for each condition. e) Functional pathway analysis was performed using the contextual language processing program COmprehensive Multi-omics Platform for Biological InterpretatiOn (COMPBIO). The spatial map depicts themes related to differentially expressed genes as nodes with interconnections depicted as edges whose thickness relates to the degree



708	Figure 2. a) Differential Interference Contrast (DIC) imaging of Intestine chips, top-down view.
709	Scale bar= 50 μ m. Representative images. b) Immunofluorescence cross section micrographs
710	showing villus like structures in the Intestine Chips. Yellow- phalloidin, Blue- Hoechst. Scale bar
711	= 50 μ m. Representetive image. c) Villus like structures height differences between Con and -
712	N/-T, Healthy and EED Intestine Chips. Healthy, p<0.000001, EED, p= 0.000685. Each symbole
713	on the graph represent an average of 4 to 5 measurment points (membrane to top of the villi)
714	measured in two to three cross section images of Intestine Chip, at leaset 2 chips per condition
715	were used. Two different Healthy donors and one EED donor were used. d)
716	Immunofluorescence longitudinal section micrographs showing mucus layer in the Intestine
717	Chips, stained with Alexa 488 conjugated lectin. Scale bar= 250 μ m. Representative images. e)
718	Apparent permeability (Papp), differences between Con and -N/-T, Healthy and EED Intestine
719	Chips. Healthy, p= 0.000005; EED, p= 0.001382. n=9 for Healthy Intestine Chips and n=8 for EED
720	Intestine Chips.




722 **Figure 3. a)** Transcriptional pathway analysis revealed a strong theme of downregulation for


721

723 genes related to fatty acid uptake when EED Chips were exposed to -N/-T media. This included

724	a 9.8-fold downregulation of the receptor CD36 (FDR < 0.001), a 10.2-fold downregulation of
725	ApoB (FDR <0.001) and an 8.2-fold downregulation of ABCC2 (FDR <0.001). There was a similar
726	trend towards downregulation when Healthy Chips were exposed to -N/-T media, but most
727	gene changes did not reach statistical significance. n = 3 chips for each condition. b) Differences
728	in ApoB corrected total fluorescence expression in Con and -N/-T Healthy and EED Intestine
729	Chips. Healthy, not significant, EED, p= 0.012284. Each symbol on the graph represent an
730	average of corrected total fluorescence expression from 3 different measurment areas of
731	Intestine Chips cross sections, from at least 2 chips per condintion. c) Differences in
732	fluorescently-labeled dodecanoic fatty acid uptake by the Intestine Chips at 5, 10, 30 and 60
733	minute time points. * <i>p</i> =0.0396, *** <i>p</i> ≤0.0008, **** <i>p</i> <0.0001. For each time point, 7 images
734	covering the entire area of a representative chip from each condition were used to calculate
735	the corrected total fluorescence expression.
736	







themes when EED Chips were exposed to -N/T media. This included a 6.2-fold downregulation

740	of MEP1B (FDR < 0.001), a 4.4-fold downregulation of SLC2A2 and a 3.3-fold downregulation of
741	XPNPEP2 (FDR < 0.01). There was occasional downregulation of these genes when Healthy
742	Chips were exposed to -N/-T media, but none that achieved statistical significance. n = 3 chips
743	for each condition. b) Heatmap showing 36 metabolites up-taken and transferred from the
744	luminal medium to the lower channel of the Intestine Chips at higher abundance in the Healthy
745	vs EED chips. n=3 for each condition. c) Venn diagram showing the number of common and
746	unique metabolites secreted by the cells in Intestine Chips.






Figure 5. a) Heatmaps showing differential expression of 9 cytokines secreted into the lumen or
 lower channel of the Con or -N/-T, Healthy and EED Intestine Chips and quantified using a bead
 based multiplexed ELISA. Color coded scale represents Log₂ fold change in expression. n=3 to 6
 for each condition.






Supplementary Figure 1. A Venn diagram representation showing overlap of differentially
regulated genes (*p*-value < 0.01, fold change > 2) for EED and Healthy Chips exposed to
complete and nutritionally deficient media. Affected genes are listed and genes that were also
differentially expressed in the clinical EED gene signature are in bold. n = 3 chips for each
condition.




758




760 downregulation for genes related to brush border localization and structural integrity when EED

- 761 Chips were exposed to -N/-T media. This included a 3.6-fold downregulation of CDHR2 (FDR <
- 762 0.01) and more modest downregulation of MYO1A (1.7-fold, FDR < 0.01) and CDHR5 (1.6-fold,
- 763 FDR < 0.05). n = 3 chips for each condition.




- 765 **Supplementary Figure 3.** SEM views of the apical surface in the Intestine Chip comparing the
- 766 morphology of Control and -N/-T treated Healthy chips. Scale bar, 20 μm (left) and 2 μm (right).
- 767 Representative images.



769 **Supplementary Figure 4.** a) Heatmap showing up and down regulated nutrients uptake and

- 770 metabolism related genes in Control and -N/-T Healthy Chips. b) Heatmap showing all ~ 23000
- up and down regulated genes in control and -N/-T healthy chips. n=4 for each condition.




772

773 Supplementary Figure 5. Calculated apparent permeability (Papp) of Gly-Sar dipeptide transfer


from the lumen to the lower channel showing differences between Con and -N/-T, in Healthy

775 Intestine Chips, in the presence or absence of Gly-Gly inhibitor. Con vs -N/-T, p= 0.0022, with vs


without inhibitor p= 0.000003. n=3 for each condition.



777



in the lower channel outflow vs lower channel inlet. n=3 for each condition.




780

781 **Supplementary Figure 7. a)** Secreted REG3A levels measured in Intestine Chips luminal


outflows. Healthy Chip, *p*=0.029, EED Chip, *p*<0.000001. n=3 to 6 for each condition. **b**) Lipocalin

783 2 (LCN2) relative expression measured by ELISA.




Supplementary Figure 8. Secreted IL-8 levels measured in the Intestine Chips lower channel
outflows, with and without peristalsis (P). Healthy Chip Con + P vs -N/-T + P, p= 0.000148; -N/-T
+ P vs -N/-T no P, p= 0.029388. EED Chip Con + P vs -N/-T + P, p= 0.000129; -N/-T + P vs -N/-T
no P, p= 0.016852. Secreted MCP-1 levels measured in the Intestine Chips lower channel

- outflows, with and without peristalsis. Healthy Chip Con + P vs -N/-T + P, p < 0.000001; -N/-T + P
- 790 vs -N/-T no P, p= 0.004174. EED Chip Con + P vs -N/-T + P, p= 0.000165; -N/-T + P vs -N/-T no P,
- 791 p= 0.000884. n=3 to 6 for each condition.




792



794 clinical EED signature with Healthy or EED Chip gene expression is depicted as a heatmap (red =

- 795 upregulation, blue = downregulation) showing the expression pattern for EED Chips in -N/-T
- 796 media vs Healthy Chips in control media. n = 3 chips for each condition.



Supplementary Figure 10. Transcriptional pathway analysis revealed a strong theme of
 downregulation for genes related to fatty acid absorption and processing when EED Chips were

- 800 exposed to -N/-T media. This included a 4.7-fold downregulation of CIDEC (FDR < 0.0001), a 4.9-
- 801 fold downregulation of CREB3L3 (FDR <0.001) and a 7.7-fold downregulation of PCK1 (FDR <
- 802 0.0001). n = 3 chips for each condition.